124 related articles for article (PubMed ID: 1909873)
1. Serum soluble CD8 molecule is a marker of CD8 T-cell activation in HIV-1 disease.
Nishanian P; Hofmann B; Wang Y; Jackson AL; Detels R; Fahey JL
AIDS; 1991 Jul; 5(7):805-12. PubMed ID: 1909873
[TBL] [Abstract][Full Text] [Related]
2. Shedding of the soluble form of the CD8 complex by CD8+/HLA-DR+ cells in HIV-1-infected patients.
Agostini C; Pizzolo G; Zambello R; Trentin L; Siviero F; Vinante F; Morosato L; Francavilla E; Cadrobbi P; Semenzato G
AIDS; 1991 Jul; 5(7):813-9. PubMed ID: 1832545
[TBL] [Abstract][Full Text] [Related]
3. Immune activation markers and AIDS prognosis.
Osmond DH; Shiboski S; Bacchetti P; Winger EE; Moss AR
AIDS; 1991 May; 5(5):505-11. PubMed ID: 1677808
[TBL] [Abstract][Full Text] [Related]
4. Immune activation markers to predict AIDS and survival in HIV-1 seropositives.
Fuchs D; Jäger H; Popescu M; Reibnegger G; Werner ER; Dierich MP; Kaboth W; Tilz GP; Wachter H
Immunol Lett; 1990 Oct; 26(1):75-9. PubMed ID: 2125976
[TBL] [Abstract][Full Text] [Related]
5. Levels of soluble CD8 antigen and circulating immune complexes in intravenous drug abusers: relationships to HIV antibody serology.
Lin RY; Nygren E; Valinsky J; Franklin M
AIDS Res Hum Retroviruses; 1989 Dec; 5(6):655-61. PubMed ID: 2514777
[TBL] [Abstract][Full Text] [Related]
6. Serum beta 2-microglobulin level increases in HIV infection: relation to seroconversion, CD4 T-cell fall and prognosis.
Hofmann B; Wang YX; Cumberland WG; Detels R; Bozorgmehri M; Fahey JL
AIDS; 1990 Mar; 4(3):207-14. PubMed ID: 1972020
[TBL] [Abstract][Full Text] [Related]
7. A distinctive form of soluble CD8 is secreted by stimulated CD8+ cells in HIV-1-infected and high-risk individuals.
Schlesinger M; Chu FN; Badamchian M; Jiang JD; Roboz JP; Goldstein AL; Bekesi JG
Clin Immunol Immunopathol; 1994 Nov; 73(2):252-60. PubMed ID: 7923932
[TBL] [Abstract][Full Text] [Related]
8. Soluble interleukin-2 receptor and soluble CD8 in serum and cerebrospinal fluid during human immunodeficiency virus-associated neurologic disease.
Griffin DE; McArthur JC; Cornblath DR
J Neuroimmunol; 1990 Jul; 28(2):97-109. PubMed ID: 2113934
[TBL] [Abstract][Full Text] [Related]
9. Immune changes in HIV-1 infection: significant correlations and differences in serum markers and lymphoid phenotypic antigens.
Bass HZ; Nishanian P; Hardy WD; Mitsuyasu RT; Esmail E; Cumberland W; Fahey JL
Clin Immunol Immunopathol; 1992 Jul; 64(1):63-70. PubMed ID: 1376654
[TBL] [Abstract][Full Text] [Related]
10. Increases in soluble CD8 antigen in plasma, and CD8+ and CD8+CD38+ cells in human immunodeficiency virus type-1 infection.
Yagi MJ; Chu FN; Jiang JD; Wallace J; Mason P; Liu Y; Carafa J; Bekesi JG
Clin Immunol Immunopathol; 1992 May; 63(2):126-34. PubMed ID: 1611715
[TBL] [Abstract][Full Text] [Related]
11. Persistent immune activation in HIV-1 infection is associated with progression to AIDS.
Hazenberg MD; Otto SA; van Benthem BH; Roos MT; Coutinho RA; Lange JM; Hamann D; Prins M; Miedema F
AIDS; 2003 Sep; 17(13):1881-8. PubMed ID: 12960820
[TBL] [Abstract][Full Text] [Related]
12. Concentrations of soluble CD95 and CD8 antigens in the plasma and levels of CD8+CD95+, CD8+CD38+, and CD4+CD95+ T cells are markers for HIV-1 infection and clinical status.
Jiang JD; Schlesinger M; Sacks H; Mildvan D; Roboz JP; Bekesi JG
J Clin Immunol; 1997 Mar; 17(2):185-92. PubMed ID: 9083895
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
Fahey JL; Taylor JM; Detels R; Hofmann B; Melmed R; Nishanian P; Giorgi JV
N Engl J Med; 1990 Jan; 322(3):166-72. PubMed ID: 1967191
[TBL] [Abstract][Full Text] [Related]
14. CD8+ T lymphocytes and progression to AIDS in HIV-infected men: some observations.
Anderson RE; Shiboski SC; Royce R; Jewell NP; Lang W; Winkelstein W
AIDS; 1991 Feb; 5(2):213-5. PubMed ID: 1903262
[TBL] [Abstract][Full Text] [Related]
15. CD8 lymphocyte counts and serum immunoglobulin A levels early in HIV infection as predictors of CD4 lymphocyte depletion during 8 years of follow-up.
Phillips AN; Sabin CA; Elford J; Bofill M; Lee CA; Janossy G
AIDS; 1993 Jul; 7(7):975-80. PubMed ID: 8102854
[TBL] [Abstract][Full Text] [Related]
16. Soluble CD8 levels in the CSF and serum of patients with multiple sclerosis.
Maimone D; Reder AT
Neurology; 1991 Jun; 41(6):851-4. PubMed ID: 1904563
[TBL] [Abstract][Full Text] [Related]
17. Increased soluble CD8 (sCD8) in human immunodeficiency virus 1-infected children in the first month and year of life.
Gesner M; Di John D; Krasinski K; Borkowsky W
Pediatr Infect Dis J; 1994 Oct; 13(10):896-8. PubMed ID: 7854890
[TBL] [Abstract][Full Text] [Related]
18. Effect of azidothymidine (AZT) on HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD8, soluble interleukin-2 receptor and tumor necrosis factor alpha levels in patients with AIDS-related complex or AIDS.
Reddy MM; McKinley G; Englard A; Grieco MH
Int J Immunopharmacol; 1990; 12(7):737-41. PubMed ID: 2127261
[TBL] [Abstract][Full Text] [Related]
19. Serum neopterin changes in HIV-infected subjects: indicator of significant pathology, CD4 T cell changes, and the development of AIDS.
Melmed RN; Taylor JM; Detels R; Bozorgmehri M; Fahey JL
J Acquir Immune Defic Syndr (1988); 1989; 2(1):70-6. PubMed ID: 2783972
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of soluble CD8 molecule in patients with lymphatic filariasis.
Lal RB; Ramzy RM; Gad AA
Immunol Lett; 1990 Oct; 26(1):85-8. PubMed ID: 2148926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
